RxDoctor Payments Data

Judith Son, MD

Internal Medicine · Olympia, WANPI 1518012632

Payments from drug & device makers

$3,848in general payments, 2019–2025

Across 174 payments — averaging $22.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$466
  • Johnson & Johnson$382
  • Pfizer$307
  • Novo Nordisk$295
  • Abbott$266
  • Lilly USA, LLC$226
  • plus $2K from 27 others

What the payments were for

  • Food & beverage$3,82699%
  • Education$221%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,848 in reported general payments places this provider in the 90th percentile of 2,038 internal medicine providers in Washington.

See all internal medicine providers in Washington

Medicare billing

Part B allowed, 2024
$39,197
Medicare patients
156
Services billed
375

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron24$21,375
OzempicSemaglutide19$17,648
TradjentaLinagliptin11$16,600
FarxigaDapagliflozin Propanediol20$15,586
EliquisApixaban14$12,291
Nano 2nd Gen Pen NeedlePen Needle, Diabetic14$1,819
Losartan Potassium122$1,748
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$1,694
Rosuvastatin Calcium88$1,502
Amlodipine Besylate141$1,427
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$1,424
Metoprolol Succinate56$1,379
Levothyroxine Sodium80$1,348
Atorvastatin Calcium88$1,222
Gabapentin54$1,219

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$35$21,37524 claims
Novo NordiskOzempic$295$17,64819 claims
Boehringer IngelheimTradjenta$213$16,60011 claims
AstraZenecaFarxiga$162$15,58620 claims
PfizerEliquis$307$12,29114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,038 internal medicine providers in Washington.

Other internal medicine in Olympia

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →